- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT04543331
Havaintotutkimus nesteen erottuvuuden ja tehokkuuden arvioimiseksi potilailla, jotka saavat Beovua uudissuonien ikään liittyvässä silmänpohjan rappeutumassa (BLUE SKY)
HavainnointitutkiMus nesteen erottuvuuden ja tehokkuuden arvioimiseksi potilailla, jotka saavat beovu-hoitoa (brolutsisumabia) uusiovaskulaarisen ikään liittyvän silmänpohjan rappeuman tärkeimpien hoitojärjestelmien mukaisesti
This study was a prospective, non-interventional, multicenter, open-label study in nAMD and DME patients being treated with brolucizumab according to the EU SmPC.
An observational study design, without a strict, mandated visit schedule or mandated treatment regimen was chosen as the most appropriate to collect available data in a real life setting. For that reason, this NIS did not impose a therapy protocol, diagnostic/therapeutic procedure or a visit schedule. The diagnostic or monitoring procedures were only those ordinarily applied to the therapeutic strategy and to routine clinical care and took place as per investigator's discretion. This included e.g. visit frequency, injection frequency and types of assessments performed - only data from routine medical practice was collected as part of the study.
Tutkimuksen yleiskatsaus
Tila
Ehdot
Interventio / Hoito
Yksityiskohtainen kuvaus
BLUE SKY consisted of the nAMD-related module BIRL (Brolucizumab In Real Life) and two general, indication-related study modules "BLUE SKY AMD" and "BLUE SKY DME".
Patients were enrolled at 40 centers, which were representatively distributed amongst the 16 German federal states. This should reflect all state-specific health insurance laws and guidelines. Naïve and pre-treated patients were included after decision to start treatment with brolucizumab and consent was given.
All patients were documented either in the AMD or DME-module (Full Analysis Set).
For the BIRL module, only naïve nAMD patients enrolled in 7 selected centers were planned to be documented. All these centers were equipped with the Zeiss PlexElite OCT-A, needed to assess and analyze BIRL specific objectives in a comparable setting. Only images from routine medical practice were collected as part of the study. The study eye was defined as the first eye treated during the study, the other eye was considered as fellow eye. If both eyes were treated at baseline, the eye with the worse VA was chosen as the study eye (if VA was measured equal, the treating ophthalmologist defines the study eye upon his discretion). The prospective observation period per patient was up to 24 months.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
Aschersleben, Saksa, 06449
- Novartis Investigative Site
-
Bayreuth, Saksa, 95445
- Novartis Investigative Site
-
Berlin, Saksa, 10713
- Novartis Investigative Site
-
Berlin, Saksa, 14163
- Novartis Investigative Site
-
Bonn, Saksa, 53105
- Novartis Investigative Site
-
Breisach, Saksa, 79206
- Novartis Investigative Site
-
Chemnitz, Saksa, 09113
- Novartis Investigative Site
-
Cologne, Saksa, 50968
- Novartis Investigative Site
-
Dresden, Saksa, 01067
- Novartis Investigative Site
-
Dresden, Saksa, 01324
- Novartis Investigative Site
-
Esslingen am Neckar, Saksa, 73728
- Novartis Investigative Site
-
Glauchau, Saksa, 08371
- Novartis Investigative Site
-
Homburg, Saksa, 66421
- Novartis Investigative Site
-
Hösbach, Saksa, 63768
- Novartis Investigative Site
-
Kiel, Saksa, 24103
- Novartis Investigative Site
-
Leipzig, Saksa, 04106
- Novartis Investigative Site
-
Magdeburg, Saksa, 39104
- Novartis Investigative Site
-
Marienberg, Saksa, 09496
- Novartis Investigative Site
-
Münster, Saksa, 48145
- Novartis Investigative Site
-
Neubrandenburg, Saksa, 17036
- Novartis Investigative Site
-
Schönebeck, Saksa, 39218
- Novartis Investigative Site
-
Stralsund, Saksa, 18435
- Novartis Investigative Site
-
Sulzbach, Saksa, 66280
- Novartis Investigative Site
-
Torgau, Saksa, 04860
- Novartis Investigative Site
-
Waren, Saksa, 17192
- Novartis Investigative Site
-
Würzburg, Saksa, 97080
- Novartis Investigative Site
-
-
Bavaria
-
Munich, Bavaria, Saksa, 81377
- Novartis Investigative Site
-
Neuburg A.d. Donau, Bavaria, Saksa, 86633
- Novartis Investigative Site
-
Würzburg, Bavaria, Saksa, 97080
- Novartis Investigative Site
-
Würzburg, Bavaria, Saksa, 97070
- Novartis Investigative Site
-
-
Hesse
-
Frankfurt am Main, Hesse, Saksa, 60590
- Novartis Investigative Site
-
-
Lower Saxony
-
Göttingen, Lower Saxony, Saksa, 37075
- Novartis Investigative Site
-
Osnabrück, Lower Saxony, Saksa, 49076
- Novartis Investigative Site
-
-
Mecklenburg-Vorpommern
-
Rostock, Mecklenburg-Vorpommern, Saksa, 18057
- Novartis Investigative Site
-
-
Rhineland-Palatinate
-
Trier, Rhineland-Palatinate, Saksa, 54296
- Novartis Investigative Site
-
-
Saarland
-
Saarbrücken, Saarland, Saksa, 66111
- Novartis Investigative Site
-
-
Saxony
-
Dresden, Saxony, Saksa, 01307
- Novartis Investigative Site
-
Leipzig, Saxony, Saksa, 04103
- Novartis Investigative Site
-
Schneeberg, Saxony, Saksa, 08289
- Novartis Investigative Site
-
-
Saxony-Anhalt
-
Halle, Saxony-Anhalt, Saksa, 06118
- Novartis Investigative Site
-
-
Thuringia
-
Jena, Thuringia, Saksa, 07740
- Novartis Investigative Site
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Näytteenottomenetelmä
Tutkimusväestö
Patients being treated for nAMD or DME with brolucizumab were enrolled in the study upon signing an informed consent.
Kuvaus
Inclusion Criteria:
The unit of analysis was patient-eye, i.e. all criteria were applied to the study eye, unless otherwise specified. Patients were included in the study if they fulfilled the following requisites:
- Diagnosis of nAMD or visual impairment due to DME
- Male and Female nAMD and DME patients with ≥18 years of age at index
- Decision to treat with brolucizumab at baseline visit
- Signed written informed consent
- Patients for whom a therapy with brolucizumab was medically indicated
- Intraretinal and/or subretinal fluid affecting the central subfield of the study eye at Screening
Exclusion Criteria:
- Patients with any contraindication or who were not eligible for treatment with brolucizumab as according to the SmPC
- Patients treated for RVO or CNV other than nAMD
- Receipt of any anti-VEGF treatment other than brolucizumab in the study eye at index date
- Central subfield of the study eye affected by fibrosis or geographic atrophy or total area of fibrosis >50% of the total lesion (nAMD)
- Any active intraocular or periocular infection or active intraocular inflammation in either eye at index date
- Patients who have been on anti-VEGF treatment for longer than 3 years (before index date)
- Any medical or psychological condition in the treating physician's opinion which may have prevented the patient from the 24 months study participation
- Patients participating in parallel in an interventional clinical trial
- Patients participating in parallel in any other NIS generating primary data for an anti-VEGF drug
- Laser photocoagulation (focal/grid or panretinal) in the study eye during the 3-month period prior to baseline
- Prior use of intraocular or periocular corticosteroids in the study eye provided at least 4 months prior to baseline
- Pregnancy and breast-feeding
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Havaintomallit: COHORT
- Aikanäkymät: PROSPECTIVE
Kohortit ja interventiot
Ryhmä/Kohortti |
Interventio / Hoito |
|---|---|
|
treatment naïve patients
Patients being the first time treated for nAMD or DME |
There was no treatment allocation. Patients administered Brolucizumab by prescription that had started before inclusion of the patient into the study were enrolled. |
|
pre-treated patients
Patients already being treated for nAMD or DME |
There was no treatment allocation. Patients administered Brolucizumab by prescription that had started before inclusion of the patient into the study were enrolled. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Percentage of patients' eyes that are absent of subretinal fluid (SRF) and intra-retinal fluid (IRF)
Aikaikkuna: Month 12
|
This outcome measure is part of the BLUE SKY AMD module. This primary study objective was addressed considering treatment naïve and pre-treated patient eyes, analyzed as two independent groups (naïve and switch). |
Month 12
|
|
Mean change in visual acuity (VA) under clinic specific routine treatment schemes
Aikaikkuna: Baseline, month 12
|
This outcome measure is part of the BIRL module. This primary study objective was addressed considering treatment naïve patient eyes. Index date (Baseline): defined as the date of the first anti-VEGF injection (brolucizumab) in patient eye. |
Baseline, month 12
|
|
Morphological CNV-Changes under clinic specific routine treatment schemes
Aikaikkuna: Baseline, month 12
|
This outcome measure is part of the BIRL module. This primary study objective was addressed considering treatment naïve patient eyes. Index date (Baseline): defined as the date of the first anti-VEGF injection (brolucizumab) in patient eye. |
Baseline, month 12
|
|
Percent of patients maintained on q12w dosing after loading through Week 52
Aikaikkuna: After loading, month 12
|
This outcome measure is part of the BLUE SKY DME module. This primary study objective was addressed considering treatment naïve patient eyes included in the study. |
After loading, month 12
|
|
Change in interval length from last interval before switch (baseline) to last interval at end of follow-up (12 months)
Aikaikkuna: Baseline, month 12
|
This outcome measure is part of the BLUE SKY DME module. This primary study objective was addressed considering pre-treated patient eyes. Index date (Baseline): defined as the date of the first anti-VEGF injection (brolucizumab) in patient eyes. |
Baseline, month 12
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Characterize nAMD patients who initiated treatment with brolucizumab with the respect to baseline characteristics
Aikaikkuna: Baseline
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Baseline
|
|
Evaluate anatomical parameters during treatment with brolucizumab
Aikaikkuna: Up to month 24
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan. |
Up to month 24
|
|
Evaluate VA change from baseline during treatment with brolucizumab
Aikaikkuna: Baseline, month 24
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan. |
Baseline, month 24
|
|
Estimate number of anti-VEGF injections, visits and injection intervals
Aikaikkuna: Up to month 24
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Estimate percentage of switchers during first 6 months and characterize switchers
Aikaikkuna: Baseline, month 6
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Baseline, month 6
|
|
Estimate discontinuation rate and time to discontinuation
Aikaikkuna: Month 1-12 and 13-24
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Month 1-12 and 13-24
|
|
Assess retreatment criteria
Aikaikkuna: Up to month 24
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Estimate the number of OCT
Aikaikkuna: Month 1-12 and 13-24
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Month 1-12 and 13-24
|
|
Assess the safety of brolucizumab
Aikaikkuna: Up to month 24
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Evaluate anatomical effectiveness
Aikaikkuna: Up to month 24
|
naive nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Evaluate treatment intervals
Aikaikkuna: Up to month 24
|
naive nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Describe implementation of treatment schemes into clinical practice
Aikaikkuna: Up to month 24
|
naive nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Evaluate morphological changes under brolucizumab treatment using multimodal imaging
Aikaikkuna: Up to month 24
|
naive nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Percentage of patient's eyes with absence of IRF and/or SRF at month 12 (naive and switch)
Aikaikkuna: Month 12
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Month 12
|
|
Evaluate anatomical parameters during treatment with brolucizumab
Aikaikkuna: Month 1-12 and 13-24
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Month 1-12 and 13-24
|
|
Characterize VA change from baseline during treatment with brolucizumab
Aikaikkuna: Month 1-12 and 13-24
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Month 1-12 and 13-24
|
|
Estimate discontinuation rate during first year of brolucizumab treatment
Aikaikkuna: Baseline, month 12
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Baseline, month 12
|
|
Estimate time to discontinuation (persistence)
Aikaikkuna: Up to month 24
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Estimate the treatment burden
Aikaikkuna: Month 1-12 and 13-24
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Month 1-12 and 13-24
|
|
Estimate the number of OCT and the number of visits with/without OCT
Aikaikkuna: Month 1-12 and 13-24
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan. |
Month 1-12 and 13-24
|
|
Assess safety of brolucizumab
Aikaikkuna: Up to month 24
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan. |
Up to month 24
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Opintojohtaja: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- CRTH258ADE02
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .